[1]范卢明,王 慧,薛 帆,等.缬沙坦联合二甲双胍治疗肥胖型高血压效果的Meta分析[J].医学信息官方网站,2022,35(15):68-71.[doi:10.3969/j.issn.1006-1959.2022.15.014]
　FAN Lu-ming,WANG Hui,XUE Fan,et al.Meta-analysis of the Effect of Valsartan Combined with Metformin in the Treatment of Obese Hypertension[J].Medical Information,2022,35(15):68-71.[doi:10.3969/j.issn.1006-1959.2022.15.014]
点击复制

缬沙坦联合二甲双胍治疗肥胖型高血压效果的Meta分析()
分享到：

《医学信息》官方网站[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年15期
页码:
68-71
栏目:
论著
出版日期:
2022-08-01

文章信息/Info

Title:
Meta-analysis of the Effect of Valsartan Combined with Metformin in the Treatment of Obese Hypertension
文章编号:
1006-1959（2022）15-0068-04
作者:
范卢明; 王 慧; 薛 帆; 等
（1.昆明医科大学护理学院，云南 昆明 650500；2.昆明医科大学第一附属医院麻醉科，云南 昆明 650032）
Author(s):
FAN Lu-ming; WANG Hui; XUE Fan; et al.
(1.School of Nursing,Kunming Medical University,Kunming 650500,Yunnan,China;2.Department of Anesthesiology,The First Affiliated Hospital of Kunming Medical University,Kunming 650032,Yunnan,China)
关键词:
缬沙坦; 二甲双胍; 肥胖型高血压
Keywords:
Valsartan; Metformin; Obese Hypertension
分类号:
R544.1
DOI:
10.3969/j.issn.1006-1959.2022.15.014
文献标志码:
A
摘要:
目的 系统评价缬沙坦联合二甲双胍治疗肥胖型高血压的效果。方法 使用计算机检索PubMed、TheCochrane Library、EMbase、CNKI、万方数据库，时限从建库至2021年7月13日，收集有关缬沙坦联合二甲双胍与单用缬沙坦治疗肥胖型高血压的临床随机对照实验，采用Review Manager 5.4软件进行Meta分析。结果 最终纳入文献6篇，共642例肥胖型高血压患者，其中试验组324例，对照组318例。治疗后,试验组SBP降低幅度[MD=-11.62，95%CI（-12.95，-10.29），P＜0.000 01]、DPB降低幅度[MD=-9.79，95%CI（-14.23，-5.35），P＜0.0001]均高于对照组，差异有统计学意义（P＜0.05）。结论 缬沙坦联合二甲双胍治疗肥胖型高血压的效果优于单用缬沙坦治疗，可有效控制血压。
Abstract:
Objective To systematically evaluate the effect of valsartan combined with metformin in the treatment of obese hypertension.Methods PubMed, TheCochrane Library, EMbase, CNKI and Wanfang databases were searched by computer. The clinical randomized controlled trials of valsartan combined with metformin and valsartan alone in the treatment of obese hypertension were collected from the database establishment to July 13, 2021. Review Manager 5.4 software was used for Meta-analysis.Results A total of 642 obese hypertensive patients were included, including 324 patients in the experimental group and 318 patients in the control group. After treatment, the decrease of SBP [MD=-11.62, 95%CI(-12.95,-10.29), P<0.000 01] and DPB[MD=-9.79, 95%CI(-14.23,-5.35), P<0.0001] in the experimental group were higher than those in the control group, and the difference was statistically significant (P<0.05).Conclusion The effect of valsartan combined with metformin in the treatment of obese hypertension is better than that of valsartan alone, which can effectively control blood pressure.

参考文献/References:

[1]郭玉华,熊良圣,聂爱蝉,等.我国高血压病流行状况及社区防治策略探讨[J].微量元素与健康研究,2012,29(6):64-67.[2]Wang L,Zhou B,Zhao Z,et al.Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18[J].Lancet,2021,398(10294):53-63.[3]王艳芬,邬东兴,张鑫鑫,等.兰州市儿童超重肥胖现状与血压、脉搏、肺活量指数的关系[J].西北民族大学学报(自然科学版),2016,37(1): 51-55.[4]黄苗,陆瑶,冷一铭,等.交感神经激活在肥胖性高血压中的作用机制[J].中国慢性病预防与控制,2019,27(12):940-943.[5]刘俊芬,刘圣君,赵自刚,等.肾素-血管紧张素-醛固醇系统在肾病发病机制中的作用[J].中国老年学杂志,2017,37(9): 2327-2331.[6]车晓宁,阮彩莲.不同级别高血压患者胰岛素抵抗、血清脂联素水平的相关性[J].中国老年学杂志,2016,36(3):711-712.[7]陈岳林,王涛,沈粤春.瘦素在高血压发病机制中的作用[J].中华高血压杂志,2015,23(9):822-827.[8]金华,金钊,张蕾蕾.肠道菌群可能为高血压发病的环境因素[J].中国微生态学杂志,2015,27(1):121-125.[9]刘兆进,郑贤,莫凤玲.二甲双胍联合厄贝沙坦治疗肥胖伴中度高血压患者的临床疗效及对血糖的影响[J].中国医药科学,2016,6(2):153-155.[10]刘鸣.系统评价、Meta-分析设计与实施方法[M].北京:人民卫生出版社,2011.[11]黄莺.二甲双胍对肥胖的原发性高血压伴糖耐量减低患者血压的影响研究[J].医学信息,2013,26(8):314-315.[12]李翠芳.缬沙坦联合二甲双胍对高血压合并代谢综合征患者血压及血液流变学的影响[J].临床军医杂志,2015,43(12):1236-1239.[13]廖火生,劳尚德.二甲双胍联合缬沙坦治疗肥胖型高血压临床疗效观察[J].广东医学,2009,30(4):630-631.[14]彭慧,陈苏,李峰,等.高血压合并代谢综合征患者接受缬沙坦联合二甲双胍治疗的降压效果及血清代谢指标评估[J].海南医学院学报,2016,22(16):1782-1785.[15]彭新翔.缬沙坦联合二甲双胍治疗高血压合并肥胖的疗效评估[J].中国农村卫生,2016(12):74-75.[16]张艳峰,冀英,汤学勤.二甲双胍联合缬沙坦硝苯地平缓释片治疗肥胖型高血压疗效观察[J].中国实用神经疾病杂志,2014,17(24):110-111.[17]Bramlage P,Pittrow D,Wittchen HU,et al.Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled[J].Am J Hypertens,2004,17(10):904-910.[18]Sarafidis PA,Bakris GL.Resistant hypertension: an overview of evaluation and treatment[J].J Am Coll Cardiol,2008,52(22):1749-1757.[19]毕欣荣,陈泽姣,陈晨晨,等.二甲双胍改善内皮细胞胰岛素抵抗作用的研究[J].中国实验诊断学,2019,23(4):684-687.

相似文献/References:

[1]乔 君,高 翔,王 瑜,等.缬沙坦对原发性高血压患者外周PBMC中IL-17表达的影响[J].医学信息官方网站,2018,31(07):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
　QIAO Jun,GAO Xiang,WANG Yu,et al.The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension[J].Medical Information,2018,31(15):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
[2]刘朝阳,张善革.二甲双胍单药及不同联合用药方案治疗2型糖尿病的随机对照研究[J].医学信息官方网站,2019,32(04):148.[doi:10.3969/j.issn.1006-1959.2019.04.048]
　LIU Chao-yang,ZHANG Shan-ge.A Randomized Controlled Trial of Metformin Monotherapy and Different Combination Regimens in the Treatment of Type 2 Diabetes[J].Medical Information,2019,32(15):148.[doi:10.3969/j.issn.1006-1959.2019.04.048]
[3]高占群,李 霜,刘 杨.立普妥与瑞舒伐他汀联合缬沙坦治疗糖尿病 并发心力衰竭的临床疗效[J].医学信息官方网站,2019,32(15):140.[doi:10.3969/j.issn.1006-1959.2019.15.045]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Efficacy of Lipitor and Rosuvastatin Combined with Valsartan in the Treatment of Diabetes Complicated with Heart Failure[J].Medical Information,2019,32(15):140.[doi:10.3969/j.issn.1006-1959.2019.15.045]
[4]田云朋,卢成志,赵向东.缬沙坦治疗慢性心功能不全合并阵发性房颤的临床疗效[J].医学信息官方网站,2019,32(13):135.[doi:10.3969/j.issn.1006-1959.2019.13.041]
　TIAN Yun-peng,LU Cheng-zhi,ZHAO Xiang-dong.Clinical Efficacy of Valsartan in the Treatment of Chronic Heart Failure Complicated with Paroxysmal Atrial Fibrillation[J].Medical Information,2019,32(15):135.[doi:10.3969/j.issn.1006-1959.2019.13.041]
[5]苗 婷,刘子艳,刘玉媛,等.二甲双胍药理作用及其机制研究[J].医学信息官方网站,2019,32(14):53.[doi:10.3969/j.issn.1006-1959.2019.14.018]
　MIAO Ting,LIU Zi-yan,LIU Yu-yuan,et al.Study on Pharmacological Action and Mechanism of Metformin[J].Medical Information,2019,32(15):53.[doi:10.3969/j.issn.1006-1959.2019.14.018]
[6]金 川,张 颖,李瑞环,等.葛根芩连汤对2型糖尿病患者糖脂代谢指标及 体重的影响[J].医学信息官方网站,2019,32(14):164.[doi:10.3969/j.issn.1006-1959.2019.14.055]
　JIN Chuan,ZHANG Ying,LI Rui-huan,et al.Effect of Gegen Qinlian Decoction on Glucose and Lipid Metabolism Index and Body Weight in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2019,32(15):164.[doi:10.3969/j.issn.1006-1959.2019.14.055]
[7]王 力,袁志强,黄晓鹏,等.前列地尔联合缬沙坦对慢性肾小球肾炎患者肾功能指标的影响[J].医学信息官方网站,2019,32(21):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
　WANG Li,YUAN Zhi-qiang,HUANG Xiao-peng,et al.Effect of Alprostadil Combined with Valsartan on Renal Function Indexes in Patients with Chronic Glomerulonephritis[J].Medical Information,2019,32(15):147.[doi:10.3969/j.issn.1006-1959.2019.21.048]
[8]尤 丽,卢 琦.甘精胰岛素联合二甲双胍治疗2型糖尿病的疗效[J].医学信息官方网站,2020,33(02):151.[doi:10.3969/j.issn.1006-1959.2020.02.046]
　YOU Li,LU Qi.Effect of Insulin Glargine Combined with Metformin in the Treatment of Type 2 Diabetes[J].Medical Information,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.02.046]
[9]孔令玲.参芪地黄汤联合缬沙坦治疗气阴两虚型早期糖尿病肾病的疗效[J].医学信息官方网站,2020,33(02):160.[doi:10.3969/j.issn.1006-1959.2020.02.050]
　KONG Ling-ling.Efficacy of Shenqi Dihuang Decoction Combined with Valsartan in the Treatment of Early Diabetic Nephropathy with Deficiency of Qi and Yin[J].Medical Information,2020,33(15):160.[doi:10.3969/j.issn.1006-1959.2020.02.050]
[10]陈钰泱,石爱杰.缬沙坦联合前列地尔治疗慢性肾小球肾炎的效果[J].医学信息官方网站,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]
　CHEN Yu-yang,SHI Ai-jie.The Effect of Valsartan Combined with Alprostadil on Chronic Glomerulonephritis[J].Medical Information,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]

更新日期/Last Update: 1900-01-01